CEBPA公司
净现值1
肿瘤科
表型
医学
生物
内科学
优势比
髓样
多元分析
等级制度
生存分析
祖细胞
髓性白血病
生物信息学
癌症
遗传学
癌症研究
总体生存率
突变
鉴定(生物学)
染色体易位
起源细胞
血液学
祖细胞
阶段(地层学)
对数秩检验
计算生物学
免疫学
比例危险模型
病态的
干细胞
基因表达谱
作者
Tomoya Komori,T Kawai,Yusuke Okuno,Shinichi Tsujimoto,Shota Kato,Tatsuya Kamitori,Satoshi Saida,Junji Ikeda,Kentaro Ohki,Motohiro Kato,Daisuke Tomizawa,Takashi Taga,Junko Takita,Keizo Horibe,Souichi Adachi,Yasuhide Hayashi,Shuichi Ito,Norio Shiba
摘要
RNA sequencing from 262 patients with paediatric acute myeloid leukaemia (AML) (JPLSG AML-12) was deconvoluted employing adult single-cell RNA-sequencing signatures and Zeng's method, which defined five cellular hierarchy subtypes: primitive, leukaemic stem/progenitor cell (LSPC)-Cycle, ProMono-like, granulocyte-monocyte progenitor (GMP)-like and intermediate. Principal component analysis revealed two main axes that distinguish paediatric from adult AML, with notable LSPC-Cycle and ProMono-like phenotype enrichment. LSPC-Cycle (>25% cycling stem-like cells) had proliferative and quiescent LSPCs, frequent French-American-British (FAB)-M7 and worst prognosis (overall survival odds ratio vs. GMP-like: 11.33). Morphology was related to the primitive (FAB-M0), GMP-like (M2/M4) and ProMono-like (M5) groups. Genomic patterns aligned with hierarchy: CBFA2T3::GLIS2, MYB::GATA1 and MECOM high expression in LSPC-Cycle; CBFB::MYH11, NUP98::NSD1 and NPM1 in the intermediate; and DEK::NUP214 and NUP98::KDM5A were concentrated in the primitive group. bZIP CEBPA and FLT3-ITD mutations clustered in the intermediate and primitive groups. Most of RUNX1::RUNX1T1 clustered in the intermediate group, whereas KMT2A::MLLT3 hierarchy differed with MECOM expression level. Paediatric AML comprised more primitive cells, rarely with mono-like/cDC-like dominance. LSPC-Cycle, FLT3-ITD and NUP98::KDM5A were considered independent prognostic factors in multivariate analysis. Findings indicate the prognostic relevance of cellular hierarchy and the importance of integrating hierarchy-specific molecular profiles for improved risk stratification and treatment formulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI